Armistice Capital »

Mineralys Therapeutics shares owned by Armistice Capital

Quarter-by-quarter ownership of Mineralys Therapeutics (MLYS) shares owned by Armistice Capital from 13F filings

Historical chart of Armistice Capital investment in Mineralys Therapeutics

Tip: Access up to 7 years of quarterly data

All positions including Mineralys Therapeutics held by Armistice Capital consolidated in one spreadsheet with up to 7 years of data

Download as csvDownload consolidated filings csv Download as ExcelDownload consolidated filings xlsx

Quarterly reported holdings in Mineralys Therapeutics by Armistice Capital

Quarter filed Position value Share count Share price at filing
2025-09-30 $19M 508k 37.92

More positions owned by Armistice Capital

Iwm Nov5 230.0 P Listed Option Put Option (IWM)
Spy Nov5 634.0 P Listed Option Put Option (SPY)
Ptc Therapeutics Ord Equity (PTCT)
Travere Therapeutics Ord Equity (TVTX)
Supernus Pharmaceuticals Ord Equity (SUPN)
Cytk Jan7 40.0 C Listed Option Call Option (CYTK)
Madrigal Pharmaceuticals Ord Equity (MDGL)
Incyte Ord Equity (INCY)
Neurocrine Biosciences Ord Equity (NBIX)
Immunovant Ord Equity (IMVT)
Dentsply Sirona Ord Equity (XRAY)
Regeneron Pharmaceuticals Ord Equity (REGN)
Freshpet Ord Equity (FRPT)
Amazon Com Ord Equity (AMZN)
Agio Dec5 40.0 C Listed Option Call Option (AGIO)

View all positions for Armistice Capital

Top funds holding Mineralys Therapeutics

Catalys Pacific
RA Capital Management
Samsara BioCapital
BlackRock
Vanguard Group
Caligan Partners
Capital Research and Management Company - Division 3
Citadel Advisors
Suvretta Capital Management
Sr One Capital Management
FMR
Franklin Resources
Point72 Asset Management
Laurion Capital Management
Farallon Capital Management

View all funds holding Mineralys Therapeutics